

#### DESCRIPTION

<b>Source</b>	<i>Spodoptera frugiperda</i> , Sf 21 (baculovirus)-derived human TACE/ADAM17 protein Arg215-Asn671, with a C-terminal 6-His tag Accession # P78536.1
<b>N-terminal Sequence Analysis</b>	Arg215
<b>Structure / Form</b>	Mature form. Recombinant Human TACE/ADAM17 may be prone to proteolytic cleavage at C-terminus. The poly-His tag may not be present in the preparation.
<b>Predicted Molecular Mass</b>	52 kDa

#### SPECIFICATIONS

<b>SDS-PAGE</b>	64 kDa, reducing conditions
<b>Activity</b>	Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH <sub>2</sub> (Catalog # ES003). The specific activity is >500 pmol/min/μg, as measured under the described conditions.
<b>Endotoxin Level</b>	<1.0 EU per 1 μg of the protein by the LAL method.
<b>Purity</b>	>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution in Tris, NaCl and Brij-35. See Certificate of Analysis for details.

#### Activity Assay Protocol

<b>Materials</b>	<ul style="list-style-type: none"> <li>Assay Buffer: 25 mM Tris, 2.5 μM ZnCl<sub>2</sub>, 0.005% Brij-35 (w/v), pH 9.0 (note: It is extremely important that the assay solution does not contain salt (CaCl<sub>2</sub>, NaCl, Na<sub>2</sub>SO<sub>4</sub>) because it inhibits TACE activity).</li> <li>Recombinant Human TACE/ADAM17 (rhTACE) (Catalog # 930-ADB)</li> <li>Substrate: MCA-Pro-Leu-Ala-Gln-Ala-Val-DPA-Arg-Ser-Ser-Arg-NH<sub>2</sub> (Catalog # ES003) , 2 mM stock in DMSO</li> <li>F16 Black Maxisorp Plate (Nunc, Catalog # 475515)</li> <li>Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent</li> </ul>
<b>Assay</b>	<ol style="list-style-type: none"> <li>Dilute rhTACE to 0.2 ng/μL in Assay Buffer.</li> <li>Dilute Substrate to 20 μM in Assay Buffer.</li> <li>In a plate load 50 μL of 0.2 ng/μL rhTACE and start the reaction by adding 50 μL of 20 μM Substrate. Include a Substrate Blank containing 50 μL Assay Buffer and 50 μL Substrate.</li> <li>Read at excitation and emission wavelengths of 320 nm and 405 nm (top read), respectively in kinetic mode for 5 minutes.</li> <li>Calculate specific activity:</li> </ol> $\text{Specific Activity (pmol/min/μg)} = \frac{\text{Adjusted } V_{\text{max}}^* \text{ (RFU/min)} \times \text{Conversion Factor}^{**} \text{ (pmol/RFU)}}{\text{amount of enzyme (μg)}}$ <p>*Adjusted for Substrate Blank **Derived using calibration standard MCA-Pro-Leu-OH (Bachem, Catalog # M-1975).</p>
<b>Final Assay Conditions</b>	Per Well: <ul style="list-style-type: none"> <li>rhTACE: 0.01 μg</li> <li>Substrate: 10 μM</li> </ul>

#### PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile, deionized water.
<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>6 months from date of receipt, -20 to -70 °C as supplied.</li> <li>3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

TACE is a member of the ADAM family that contains A Disintegrin And Metalloprotease-like domain. Like other membrane-anchored ADAMs, TACE consists of a pro domain with a cysteine switch and furin cleavage sequence, a catalytic domain with the zinc-binding site and Met-turn expected for reprotolysins, a disintegrin-like domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and the cytoplasmic domain. In addition to its ability to release the 17 kDa extracellular form of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) from the 26 kDa membrane-anchored TNF- $\alpha$ , TACE also plays an essential role in shedding ectodomains from a variety of proteins such as L-Selectin, Transforming Growth Factor- $\alpha$ , Amyloid Protein Precursor, and Notch-1 receptor. TACE mRNA is present in virtually every tissue and TACE protein resides both on the cell surface and in the cell.

**References:**

1. Black, R.A. and J.D. Becherer (1998) in *Tumor Necrosis Factor  $\alpha$ -Converting Enzyme*. Barrett, A.J. et al. (eds): Handbook of Proteolytic Enzymes, San Diego: Academic Press, p. 1315.
2. Primakoff, P. and D.G. Myles (2000) Trends in Genetics **16**:83.